M Raheel Khan

Medical Oncology Consultant St James Hospital, Special Interest in GU, Gynae and Germ Cell Tumours, Lead Investigator SLECT Trial

[M Raheel Khan @RKhanOnc]

As we see rise in cancer incidence and survival rates, it’s becoming more important to understand #CancerSurvivors
We assessed #TesticularCancer pts for late side effects, one of the first solid organ cancer to be cured thanks to Dr Einhorn @IndianaUniv

@cancertrials_ie
@TUH_Tallaght
@TUHCancerTrials
@TestesCancer
@TCSociety
@MASCC_JSCC

https://t.co/Ot8E8ALhGq

[Amanda Nizam, MD @AmandaNizamMD]

Important review on EV+P toxicities from colleagues @MayoCancerCare. Causal attributions are incredibly challenging due to patient heterogeneity & the many overlapping toxicities between EV and P.

Great read for oncologists who treat multiple cancers since SOC EV+P use is currently limited to MIBC and la/mUC.

@OncoAlert @DrKarineTawagi @LauraBukavinaMD @IBCG_BladderCA @BladderCancerUS

[M Raheel Khan @RKhanOnc]

@PeterMacCC ➡️➡️ @CancerInstIRE
A timely delivery from #GUCast
@gu_onc @declangmurphy
Such a lovely present 🎁 😍

Go raibh mile maith agat

[M Raheel Khan @RKhanOnc]

@US_FDA approval Hits different when you have worked on the study
Thinking of all the patients, families, staff and colleagues involved
A badge of honour for @TUH_Tallaght trials unit @cancertrials_ie @RayMcDermott1
✅Highest recruitment
✅Successful agency inspection
10/10

[Toni Choueiri, MD @DrChoueiri]

JUST IN: @FDA approves the combo of Lenvatinib+HIF2 inhibitor Belzutifan in advanced clear cell renal cell carcinoma following PD1/L1 inhibitor. Results based on Litespark-011 trial led by @motzermd @DrDanielHeng @SchmidigerManu1

@ASCO @myESMO @AACR @kidneycan @DanaFarber_GU @OncoAlert

[Toni Choueiri, MD @DrChoueiri]

JUST IN: @FDA approves the combo of Lenvatinib+HIF2 inhibitor Belzutifan in advanced clear cell renal cell carcinoma following PD1/L1 inhibitor. Results based on Litespark-011 trial led by @motzermd @DrDanielHeng @SchmidigerManu1

@ASCO @myESMO @AACR @kidneycan @DanaFarber_GU @OncoAlert

[M Raheel Khan @RKhanOnc]

Great news for #KidneyCancer pts
I hope it will be available in Ireland soon
@TUH_Tallaght was among highest 🔝recruiting sites globally
We know it’s very well tolerated in Irish cohort
🌅Life saving for many pts
@UCANIRELAND
@ipha
@hseNCCP

[Yüksel Ürün @DrYukselUrun]

New @FDA approval in advanced kidney cancer: belzutifan + lenvatinib after prior PD-1/PD-L1 therapy.
Another meaningful option after IO.

@KidneyCancer @kidneycan @IKCCorg @OncoAlert @OpenMedicineHQ

[Yüksel Ürün @DrYukselUrun]

New @FDA approval in advanced kidney cancer: belzutifan + lenvatinib after prior PD-1/PD-L1 therapy.
Another meaningful option after IO.

@KidneyCancer @kidneycan @IKCCorg @OncoAlert @OpenMedicineHQ

[Niamh Coleman, MD PhD @niamhjcoleman]

It’s finally out! 🎉

Next-Generation Tumor-Agnostic Targets on the Horizon 🎯

What comes after MSI-H, TMB-H, NTRK and the first generation of tumor-agnostic therapies? 💊We explore the emerging targets, biology and drug-development strategies that could define the next wave of tumor-agnostic precision oncology 🧬🔬

🔗 https://t.co/gdRO4afL7d

#PrecisionOncology #TumorAgnostic #EarlyDrugDevelopment

[M Raheel Khan @RKhanOnc]

Agree 💯
A lot of support and funding available
Protected time biggest hurdle for doctors and nurses

[Mark Henry @Mark_J_Henry]

Academic freedom in Ireland is one of the highest in the world. Students and lecturers can pursue their studies without political direction or interference. That fosters innovation and encourages critical thinking. And it's something to be proud of 🇮🇪

[M Raheel Khan @RKhanOnc]

"RESISTANCE EXERCISES"

are required to prevent sarcopenia and treatment related complications in prostate cancer patients

Here at @stjamesdublin and @CancerInstIRE we have desinged a comprehensive program with help of our physiotherapy colleagues @sheillg and our survivorship nurse @Bridor

I hope it becomes a standard of care in every cancer department treating #ProstateCancer

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

🏃‍♂️ Are we doing enough to make exercise part of supportive care for advanced prostate cancer?

https://t.co/1TjTJ6iZgd

Prevalence of meeting aerobic physical activity and resistance training guidelines in advanced prostate cancer: a descriptive study of racial and regional disparities in the IRONMAN💪 registry

In 2,485 participants from the international IRONMAN registry, 58–63% met aerobic activity guidelines, but only 19–23% achieved recommended resistance training levels. Participation was particularly low in African 🌍 regions, where just 0–3% met resistance training guidelines.
➡️ Black participants and those from Africa had lower odds of meeting aerobic activity recommendations.
✅ The findings highlight important geographic and racial disparities and the need for tailored exercise strategies in advanced prostate cancer care.

@Alekssolberg1, @nat_greaves, @Prof_IanD, @DrAndreFay, @DebEnting, @RayMcDermott1, @SimoneBadal, @APoopola, @JohnLazarus01, @quimmateo, @bjartell, @AOmlin, @camilleragin, @loreleimucci, @IRONMANregistry

@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists

[Patrick Forde @FordePatrick]

Three lung cancer phase 3 trials selected for presidential sessions at #ESMO26 ! I have been honoured to chair the metastatic lung track this year w 2 proffered paper & 2 rapid oral sessions & even more phase 3 trial results in EGFR lung cancer, radiation, & IO! #lcsm @myESMO

[Atanas G. Atanasov @_atanas_]

An experimental blood test detected 87% of early-stage pancreatic ductal cancers in an international study.

[M Raheel Khan @RKhanOnc]

🚨 Potential new SOC

If available will be a game changer especially in gynae cancer patients where CIT is huge problem after pelvic RT and chemo, even with young ones

[Journal of Clinical Oncology @JCO_ASCO]

Now out in #JCO 👇
Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in Gastrointestinal Cancers: The Phase II ACT-GI Trial. Co-authored by @HannyAlSamkari.

Read the article. https://t.co/4o0Y8ijBGt

[Big Timi @OrevaZSN]

I love how Outlook deletes meeting emails the moment I hit accept. It’s a genius idea, because obviously I’ll never need the agenda, Zoom link, meeting details, or literally anything else from that email again. Truly incredible software.

[M Raheel Khan @RKhanOnc]

Great work @Shotoole81 👏🏼👏🏼👏🏼
#WorldGODay

[Sharon O'Toole @Shotoole81]

A big thank you to @CarrollJennifer for supporting the launch of @WorldGOday in Ireland highlighting the 5 #gynaecancers @hseNCCP @HSELive Check outhttps://thisisgo.ie/world-go-day for info on events happening across Ireland

[M Raheel Khan @RKhanOnc]

@Bridor we should pilot this in @CancerInstIRE 😀

#CancerSurvivors

[Adam B. Weiner, MD @Adam_Weiner535]

⛳ Golf as #ProstateCancer survivorship medicine? Small but neat feasibility data ⛳

@FrontOncology, GREENS single-arm pilot in men on ADT:

🏌️‍♂️ 15 enrolled, 10 completed a 10-wk group golf + exercise program

✅ 90% attendance, 98.9% within-session adherence
✅ Zero grade 2+ adverse events
✅ High enjoyment and satisfaction, mean 7/7 willingness to recommend

⚠️ Small, single-arm, no control or oncologic endpoints

🎯 Men stuck with the program and loved it & adherence is critical in this space

🔗 https://t.co/ICx2F8A8gZ
@AmerUrological @UroOnc @justindubinmd @UrologyTimes @urotoday @PCF_Science @PCFnews

[Adam B. Weiner, MD @Adam_Weiner535]

⛳ Golf as #ProstateCancer survivorship medicine? Small but neat feasibility data ⛳

@FrontOncology, GREENS single-arm pilot in men on ADT:

🏌️‍♂️ 15 enrolled, 10 completed a 10-wk group golf + exercise program

✅ 90% attendance, 98.9% within-session adherence
✅ Zero grade 2+ adverse events
✅ High enjoyment and satisfaction, mean 7/7 willingness to recommend

⚠️ Small, single-arm, no control or oncologic endpoints

🎯 Men stuck with the program and loved it & adherence is critical in this space

🔗 https://t.co/ICx2F8A8gZ
@AmerUrological @UroOnc @justindubinmd @UrologyTimes @urotoday @PCF_Science @PCFnews

[Yakup Ergün @dr_yakupergun]

The AACR Cancer Progress Report 2026 is out.

It provides a remarkable snapshot of how much cancer outcomes have changed over the past few decades.

In the US, the cancer death rate fell by 35% between 1991 and 2024, translating into an estimated 4.8 million cancer deaths avoided.

Five-year survival across all cancers has increased from 49% in the mid-1970s to 71% today. Even in metastatic disease, 5-year survival has risen from 17% in the mid-1990s to 36%.

For some cancers, the change has been particularly striking. Breast cancer mortality has fallen by 44% since 1989, while colorectal cancer mortality has declined by about 50% since 1990.

There are still major areas where progress has been limited. Five-year survival remains only 13.7% for pancreatic cancer and 6.6% for glioblastoma. Mortality from early-onset colorectal cancer has also been increasing since 2004.

The report also highlights persistent disparities in access to biomarker testing, immunotherapy, clinical trials, and guideline-concordant treatment.

https://t.co/O9YErhnUj1